ISPOR 20th annual European congress

ISPOR 20th annual European congress

From 4th to 8th November 2017 it will be held in Glasgow, Scotland, the ISPOR 20th annual European congress. ISPOR is recognized globally as the leading scientific and educational organization for HEOR (health economics and outcomes research) and its use in health care decisions. ISPOR Glasgow provides a forum for discussion and dissemination of HEOR information. The congress is a great opportunity collaborate and network with colleagues in the field, and hear about innovative research methods and new health policy developments. Reflecting on revolutionary transformations affecting today’s health care, ISPOR Glasgow will address medical technology development, health technology assessment, and policy and clinical decision making while exploring the theme, The Evolution of Value in Health Care. Dr. Sola Morales will discuss about the topic that in 1999, the EU enacted legislation to foster the introduction of new Orphan Medicinal Products (OMP) into the market. To date only partial evaluations of the success of this legislation have been made, so this analysis investigates the outcomes of the OMP legislation from a broader perspective. It is possible to find the program in this...
XXXVII Jornadas de economía de la salud

XXXVII Jornadas de economía de la salud

Taking part in the XXXVII Jornadas de economía de la salud. The days 6th to 8th of September of 2017, in Barcelona, the societies AES and SEE, two of the founders of SESPAS, has organised this congress with the aim of creating a scientific joint meeting to build up, with the mainstream of different topics proposed, an alliance between the different organizations that has come to the workshop. This congress tries to accompany the process of interconnecting the European and worldwide public health networks. And, putting the Spanish public health and health administration on the map. Topics like global warming, social inequality related with health, education, vertical social mobility or big data are covered during the different boards that have took place in this congress. As we know, health problems of the population are complex, with many different causes and effects, that requires a multidisciplinary work; epidemiology, the economy, the healthcare management, environmental health, among others. Those questions have been exposed during the workshop to be able to analyse the problems and solutions of the public health. Specifically, Dr. Sola Morales has participated in the pharmaceutical policies board exposing the topic: Has OMP legislation been successful: an empirical analysis. The final program is available in this web...
Third workshop on drugs pricing in Milan

Third workshop on drugs pricing in Milan

The objective of this workshop was achieving a multistakeholder work table discussing about issues related to drugs pricing, focusing the horizon scanning, access to innovation, current and future role of insurances and private providers. This seminar was hold the 4th and 5th of May, 2017 in Mila, Italy, by maprovider . Where Dr. Oriol Solà-Morales gave a talk regarding the decentralized HTA process I the case of...
RWE as a Management Tool

RWE as a Management Tool

Dr. Solà-Morales was invited to give a presentation in a plenary session at the 20th National Hospital Congess (Sevilla, dates) on uses of Real World Evidence (RWE). Building on his own experences, Dr. Solà-Morales explained how to use RWE as an effective management tool to implement effective interventions with clinicians, while encouraging clinicians empowerment. Coming from Eminence Based Medicine, extensive use of Randomised Clinical Trials led to the introduction of evidence based medicine, a more accurate medical practice with far less variability and better outcomes. By introducing Clinical Practice Guidelines, policymakers ensured the effective interventions were spread across the population, but without much control on effectiveness. But that has come at a cost of clinician’s autonomy. And the lack of external validity of data. Yet, some of the most important transformations of healthcare come from large observational trials (i.e Framingham study…) With the introduction of RWE, there is the opportunity to pair again efficacy and effectiveness, and at the same time to empower clinicians to make local adaptations of the CPG to ensure the most effective interventions are delivered at the patient level, making again local decisions relevant for both the physician and the...
“Cal definir a l’inici del desenvolupament d’un fàrmac l’estratègia de regulació i esbrinar qui és el client en cada cas”

“Cal definir a l’inici del desenvolupament d’un fàrmac l’estratègia de regulació i esbrinar qui és el client en cada cas”

hitt ha participat a la jornada Lessons Learned: Market Access and Reimbursement organitzada per l’associació d’empreses CataloniaBio i Biocat el passat 29 de novembre al Parc Científic de Barcelona, on també s’han pogut escoltar i debatre les lliçons apreses d’altres experts consultors i de la indústria del sector. Sota la moderació de Pepi Hurtado, PhD – Sòcia, Insights in Life Sciences (ilS), la taula rodona ha comptat com a ponents amb: Antoni Gilabert, gerent de Farmàcia i del Medicament, Servei Català de la Salut Carme Pinyol, directora general, INNOVA-strategic consulting Oriol Solà-Morales, director general, HITT Òscar Pérez, director de Regional access & Business, Celgene Laura E. Ayzin, directora de Relacions institucionals i Market access, Ferrer Les jornades Lessons Learned: Compartint experiències per a impulsar la competitivitat que organitzen l’associació d’empreses CataloniaBio i Biocat són un fòrum de coneixement i networking adreçat als professionals d’empreses de l’àmbit de les ciències de la vida i la salut. Tenen com a objectiu compartir experiències i reflexions en diferents àrees estratègiques de coneixement i capacitats necessàries per reforçar la competitivitat de les empreses biotecnològiques i biomèdiques. CataloniaBio és l’associació d’empreses de l’àmbit de les ciències de la vida i la salut a Catalunya. La seva missió és representar i donar suport a les companyies interessades en promoure un clúster estratègic i innovador, així com participar en la definició del marc d’actuació sectorial i les polítiques industrials que dissenyin tant les administracions del nostre país com les europees. L’associació es va crear el 2006 de la mà d’un grup d’emprenedors, i actualment compta amb més de 90 empreses que tenen una activitat rellevant en R+D+I entre multinacionals, pimes, start-up i spin-off. LLEGIR LA CRÒNICA COMPLETA DE LA...
hitt participa en el desayuno ilS sobre Market Access y Acuerdos Innovadores – Barcelona 25 de febrero

hitt participa en el desayuno ilS sobre Market Access y Acuerdos Innovadores – Barcelona 25 de febrero

El próximo jueves 25 de febrero hitt participará en la mesa redonda sobre “Acceso al Mercado y Acuerdos Innovadores en España” convocada por Insights in Life Sciences (ilS) i CataloniaBio, que tendrá lugar en el Parc Científic de Barcelona y contará con la participación de representantes del Institut Català d’Oncología, CatSalut y Almirall. Descarga el programa completo...